Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 17

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 17
---
July 2, 2025, the Compensation Committee of the Board of Directors approved the grant of an aggregate of 357,448
stock options issued to certain executives with an exercise price equal to the closing price of the Company’s common stock on
the grant date, a ten-year10
term, and which vest in equal annual installments over a three-year period, subject to continued employment. In addition, the
Compensation committee approved cash bonuses totaling $449,000
payable to certain officers and a third-party advisor for services render through December 31, 2024. However, the payment of such
amounts is contingent upon the Company maintaining cash on hand of at least $3,500,000.
Accordingly, no payments will be made until this condition is satisfied. The Company accrued for the liability as of June 30,
2025.

On July 16, the Company entered into a
amendment with a warrant holder who holds warrants exercisable for 1,249,999
shares of common stock that clarified the exercise mechanisms. Concurrently with the amendment, the warrant holder exercised the
warrants via a cashless exercise and received 913,299
shares. Pursuant to the amendment, the Company agreed to issue the warrant holder 86,700
shares of common stock by August 31, 2025.

On August 12, 2025, the Company received an
exercise notice from a warrant holder who holds warrants exercisable for 109,376
shares of common stock. The warrants were exercised via a cashless exercise, and the warrant holder received 30,547
shares of common stock. Pursuant to the amended warrant agreement, the warrant holder will be issued 56,954
shares of common stock by August 31, 2025.

22

ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial information
and related notes included in our Annual Report on Form 10-K for fiscal 2024, which was filed with the Securities and Exchange Commission,
or the SEC, on March 28, 2025, or the Annual Report.

Special
Note Regarding Forward-Looking Statements

All
statements other than statements of historical fact included in